RxDoctor Payments Data

Adel Kadous, MD

Family Medicine · Anthony, NMNPI 1518318096

Payments from drug & device makers

$536in general payments, 2019–2025

Across 21 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$119
  • Boehringer Ingelheim$107
  • Novo Nordisk$99
  • Lilly USA, LLC$95
  • Exact Sciences$39
  • Abbott$24
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$47188%
  • Education$6512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$536 in reported general payments places this provider in the 70th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$49,260
Medicare patients
68
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$172,079
TrulicityDulaglutide114$149,496
FarxigaDapagliflozin Propanediol47$66,272
RybelsusSemaglutide21$50,355
JardianceEmpagliflozin26$38,112
MounjaroTirzepatide21$31,174
CreonLipase/Protease/Amylase23$30,442
EliquisApixaban23$28,779
XareltoRivaroxaban16$14,538
Tresiba Flextouch U-100Insulin Degludec12$11,688
SymbicortBudesonide/Formoterol Fumarate19$8,029
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$6,885
Diclofenac Sodium104$3,805
Rosuvastatin Calcium196$2,791
Gabapentin103$2,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$99$222,433154 claims
Lilly USA, LLCTrulicity, Mounjaro$95$180,671135 claims
Boehringer IngelheimJardiance$107$38,11226 claims
AbbVieCreon$14$30,44223 claims
PfizerEliquis$21$28,77923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Anthony

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →